We are live on ! Find out more
EPIX

ESSA Pharma
EPIX

Delisted

EPIX was delisted on the 8th of October, 2025.

Back to rankings

12 hedge funds and large institutions have $19.2M invested in ESSA Pharma in 2015 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding

Funds holding: 10 → 12 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

27% less capital invested

Capital invested by funds: $26.4M → $19.2M (-$7.2M)

Holders
12
Holders Change
+2
Holders Change %
+20%
% of All Funds
0.31%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
+$178K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$78.6K
3
UBS Group
UBS Group
Switzerland
+$5.43K

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$66.8K
2
Morgan Stanley
Morgan Stanley
New York
-$46.1K

EPIX Hedge Fund Activity: Q4 2015 in Review

12 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q4 2015, worth a combined $19.2M — down 27% from $26.4M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new EPIX positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Acuta Capital Partners, adding an estimated $178K. The largest seller was Acadian Asset Management, cutting an estimated $66.8K.

  • 12 institutional investors held ESSA Pharma (EPIX) as of Q4 2015, up from 10 in Q3 2015.
  • Funds reported $19.2M of ESSA Pharma stock for Q4 2015, down 27% quarter-over-quarter.
  • 2 funds opened new ESSA Pharma positions in Q4 2015 and 0 closed out, a net change of +2 holders.
  • The largest ESSA Pharma buyer in Q4 2015 was Acuta Capital Partners, an estimated $178K added.
  • The largest ESSA Pharma seller in Q4 2015 was Acadian Asset Management, an estimated $66.8K sold.

Based on aggregated 13F filings for Q4 2015.